Neurotrophic Keratopathy Completed Phase 2 Trials for Cenegermin (DB13926)
Also known as: Neurotrophic Keratitis / Neurotrophic keratitis (disorder)
| Indication | Status | Phase |
|---|---|---|
| DBCOND0077055 (Neurotrophic Keratopathy) | Completed | 2 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02227147 | Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK | Treatment |